[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

4D Molecular Therapeutics Inc 5858 HORTON STREET SUITE 455 EMERYVILLE CA 94608 USA

www.4dmoleculartherapeutics.com Employees: 196 P: 510-505-2680

Sector:

Medical

Description:

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.

Key Statistics

Overview:

Market Capitalization, $K 482,432
Enterprise Value, $K 422,192
Shares Outstanding, K 51,051
Float, K 46,150
% Float 90.40%
Short Interest, K 11,519
Short Float 22.56%
Days to Cover 16.29
Short Volume Ratio 0.69
% of Insider Shareholders 9.60%
% of Institutional Shareholders 99.27%

Financials:

Annual Sales, $ 85,210 K
Annual Net Income, $ -140,110 K
Last Quarter Sales, $ 85,090 K
Last Quarter Net Income, $ 19,400 K
EBIT, $ -159,550 K
EBITDA, $ -159,590 K

Growth:

1-Year Return 182.04%
3-Year Return -44.21%
5-Year Return -71.19%
5-Year Revenue Growth 526.08%
5-Year Earnings Growth 72.56%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.43 on 03/18/26
Next Earnings Date 05/14/26 [--]
Earnings Per Share ttm -2.42
EPS Growth vs. Prev Qtr 142.57%
EPS Growth vs. Prev Year 147.78%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

FDMT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -31.75%
Return-on-Assets % -28.30%
Profit Margin % -164.43%
Debt/Equity 0.00
Price/Sales 5.63
Price/Cash Flow N/A
Price/Book 1.06
Book Value/Share 8.85
Interest Coverage -1.86
60-Month Beta 2.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.